AstraZeneca PLC
AZN Real Time Price USDRecent trades of AZN by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in AZN holdings by institutional investors
Quarterly net insider trading by AZN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,680,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Copyright/Patent/Trademark Tariff (miscellaneous tariff bills) Trade (domestic/foreign) Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code
-
$2,280,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills) Trade (domestic/foreign)
-
$670,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,350,000 Oct 17, 2025 Issue: Pharmacy Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,840,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,240,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$640,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Insurance
-
$650,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$80,000 Feb 07, 2024 Issue: Health Issues Medicare/Medicaid Pharmacy Budget/Appropriations
-
$830,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
Former government officials who have lobbied for AZN
63 former government officials from 38 congressional offices at 11 lobbying firms have lobbied for AZN, most recently Sep 16, 2026.
-
Matthew Schuck House New Communications Dir., House Budget Committee/Rep. Jason Smith; Communications Dir., Rep. Sean Duffy; Press Sec., Rep. Mark Sanford; Dir. of Strategic Communications, HUD; White House Liaison, USAGM -
Michael Williams House New Associate Deputy General Counsel, OMB; Deputy Asst. to President and Counselor to the White House Chief of Staff; Acting General Counsel, Department of Housing and Urban Development
-
Aleix Jarvis Senate New Legislative Director, Senator Lindsey Graham; Legislative Director, Rep. Lindsey Graham; Legislative Assistant, Rep. Lindsey Graham; Staff Assistant, Rep. Charles Taylor -
Matthew Schuck House New Communications Dir., House Budget Committee/Rep. Jason Smith; Communications Dir., Rep. Sean Duffy; Press Sec., Rep. Mark Sanford; Dir. of Strategic Communications, HUD; White House Liaison, USAGM
-
Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg -
Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie -
Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
AZN Estimated quarterly lobbying spending
AZN Revenue by Segment or Geography
New AZN patent grants
-
Patent Title: Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide Nov. 08, 2016
-
Patent Title: Nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) Oct. 25, 2016
-
Patent Title: Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient Oct. 18, 2016
-
Patent Title: Crystal structures of sglt2 inhibitors and processes for preparing same Sep. 27, 2016
-
Patent Title: Arginase inhibitors and methods of use thereof Sep. 20, 2016
-
Patent Title: Methods for improving asthma symptoms using benralizumab Sep. 13, 2016
-
Patent Title: Methods for increasing forced expiratory volume in asthmatics using benralizumab Sep. 13, 2016
-
Patent Title: Methods for reducing exacerbation rates of asthma using benralizumab Sep. 13, 2016
-
Patent Title: Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer Aug. 30, 2016
-
Patent Title: Chemical compounds Aug. 23, 2016
-
Patent Title: Combinations comprising (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Aug. 02, 2016
-
Patent Title: Benzoxazinone amides as mineralocorticoid receptor modulators Jul. 19, 2016
-
Patent Title: Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor Jun. 28, 2016
-
Patent Title: Azaindole derivatives Jun. 21, 2016
-
Patent Title: Coated tablet formulation and method May. 17, 2016
-
Patent Title: Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits Apr. 12, 2016
-
Patent Title: Methods and compositions for treating asthma Mar. 29, 2016
-
Patent Title: Inhaler with indexing linked to movement of cover Mar. 22, 2016
-
Patent Title: Dispenser and method for entraining powder in an airflow Mar. 15, 2016
-
Patent Title: Inhaler 624 Feb. 09, 2016
-
Patent Title: Chemical compounds Feb. 02, 2016
-
Patent Title: Compounds and their use as bace inhibitors Feb. 02, 2016
-
Patent Title: Compound Dec. 29, 2015
-
Patent Title: Dispenser and method for entraining powder in an airflow Dec. 15, 2015
-
Patent Title: Pharmaceutical formulations containing an sglt2 inhibitor Dec. 01, 2015
-
Patent Title: Vial cap 187 Nov. 03, 2015
-
Patent Title: Inhaler comprising a base having a plurality of medicament containing sealed cavities Nov. 03, 2015
-
Patent Title: Chemical compounds Oct. 13, 2015
-
Patent Title: Breath activated inhaler Oct. 13, 2015
-
Patent Title: Chemical compounds Oct. 13, 2015
-
Patent Title: Chemical compounds Oct. 13, 2015
-
Patent Title: Crystalline naloxol-peg conjugate Oct. 06, 2015
-
Patent Title: Bis-(sulfonylamino) derivatives for use in therapy Sep. 29, 2015
-
Patent Title: Ticagrelor co-crystal Aug. 11, 2015
-
Patent Title: Inhalation device and method of dispensing medicament Aug. 04, 2015
-
Patent Title: Process for the preparation of benzyl [(3as,4r,6s,6ar)-6-hydroxy-2,2-dimethyltetrahydro-3ah-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and intermediates in the process Jul. 14, 2015
-
Patent Title: Inhibitors of protein kinases Jun. 30, 2015
-
Patent Title: Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor Jun. 30, 2015
-
Patent Title: Medicament-containing dispenser provided with a display for presenting indicia to a user Jun. 16, 2015
-
Patent Title: Bilayer tablet formulations Jun. 09, 2015
-
Patent Title: Imidazoquinoline compounds Jun. 02, 2015
-
Patent Title: Melanocortin receptor-specific peptides May. 26, 2015
-
Patent Title: Quinazoline derivatives as vegf inhibitors May. 26, 2015
-
Patent Title: Chemical compounds 542 May. 26, 2015
-
Patent Title: Ethanamine compounds and methods of using the same May. 19, 2015
-
Patent Title: Cyclopropyl amide derivatives May. 12, 2015
-
Patent Title: Chromenone derivatives May. 12, 2015
-
Patent Title: Chemical compounds Apr. 28, 2015
-
Patent Title: Phosphonoxy quinazoline derivatives and their pharmaceutical use Apr. 28, 2015
-
Patent Title: Crystalline naloxol-peg conjugate Apr. 21, 2015
Federal grants, loans, and purchases
- $1,860 2025-12-29 00:00:00 Agency: Department of Health and Human Services
- $2,134 2025-12-29 00:00:00 Agency: Department of Health and Human Services
- $1,810 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $2,076 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $0 2024-04-24 00:00:00 Agency: Department of Veterans Affairs
- $2,023 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $1,764 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $20,322 2023-07-27 00:00:00 Agency: Department of Health and Human Services
Estimated quarterly amount awarded to AZN from public contracts
Recent insights relating to AZN
Recent picks made for AZN stock on CNBC
ETFs with the largest estimated holdings in AZN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AZN stock a Buy, Sell, or Hold?
- What is the price target for $AZN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AZN stock?
- Who owns the most shares of $AZN stock?
- What funds own $AZN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AZN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
AstraZeneca PLC (AZN) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for AstraZeneca PLC (AZN).
Quiver Premium charts AZN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at AZN, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|